This message contains images. If you don't see images, click here to view.
Advertise in this news brief.

Text Version    RSS    Subscribe    Unsubscribe    Archive    Media Kit           February 18, 2015

Home     About SGO    Education    Membership    Clinical Practice    Public Policy    Blog    Partnerships    Store


Hormone replacement therapy may increase ovarian cancer risk
Medscape (Free login required)
Hormone replacement therapy (HRT) was significantly associated with an increased risk for ovarian cancer in postmenopausal women, according to an extensive meta-analysis from the Collaborative Group on Epidemiological Studies of Ovarian Cancer. "The findings that ovarian cancer risk is greatest in current users of hormone therapy, falls after use ceases, and varies by tumour type, strongly suggest a causal relationship," the researchers write.
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Featured guests and speakers at the SGO Annual Meeting
The SGO Annual Meeting on Women's Cancer in Chicago on March 28-31 will have a number of featured guests and speakers to address some of the top issues that impact health care providers today, from “Leadership Under Pressure and Flexible Thinking” with Bruce Craven to the “Gyn Onc Wellness Retreat” with Kell Julliard. Register today through
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


FDA grants Reolysin orphan drug designation for ovarian cancer
The FDA has granted an orphan drug designation to Reolysin (wild-type reovirus) for the treatment of patients with ovarian cancer, according to the developer of the immunotherapy, Oncolytics Biotech, Inc. Reolysin is currently being studied in an ongoing randomized phase II trial (GOG186H) in combination with weekly paclitaxel versus weekly paclitaxel alone in patients with persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer. The trial completed enrollment in September 2014.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

  ChemoFx Improves Ovarian Cancer Outcomes
ChemoFx® provides invaluable information to physicians choosing from 20+ equivalent treatment recommendations without prior knowledge of how individual patients may respond. ChemoFx determines platinum resistance in primary ovarian cancer and demonstrates longer overall survival by 14 months in recurrent ovarian cancer, making it instrumental in improving patient outcomes.


Study: Doctors' assumptions on sex heighten lesbians' cervical cancer risk
Lesbians may be at higher risk of cervical cancer because they get fewer screenings than heterosexual women, due partly to doctors' sometimes incorrect assumptions about their sexual history, University of Washington researchers said. Although nearly all cases of cervical cancer are attributable to a human papillomavirus, or HPV, infection, healthcare providers often do not encourage lesbian patients to get regular HPV screenings, the researchers found. That is because the disease is most commonly transmitted during heterosexual sex and doctors may wrongly assume lesbians have only had sex with other women, despite studies that have found most lesbians and their partners have had sex with men, according to the study published in The Nurse Practitioner.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Many women willing to extend cervical cancer screening intervals
Cancer Network
Women in routine gynecologic care expressed willingness to extend intervals between screenings to a certain extent, and to use cytology alone or Pap-Human Papillomavirus (HPV) cotesting if recommended by a physician, according to a new survey. “HPV cotesting with a 3-year screening interval has been an acceptable option since 2003, yet uptake of cotesting in clinical practice has been slow,” wrote researchers led by Patti E. Gravitt, PhD, MS, of the University of New Mexico in Albuquerque. She and colleagues conducted a survey of 551 women aged 36 to 62 who were enrolled in the Human Papillomavirus in Perimenopause Study to assess attitudes toward new cervical cancer screening options. Results were published in the February issue of Obstetrics & Gynecology.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Ability to conceive not threatened by cervical treatment
MedPage Today
A woman's ability to conceive did not change following procedures to evaluate and treat cervical abnormalities, a large cohort study showed. Women who received surgical treatment actually had a 42 percent higher pregnancy rate compared with women who did not undergo cervical treatment or diagnostic procedures. The pregnancy rate was similar between women who had treatment or diagnostic procedures. The findings published in PLoS One should go a long way toward resolving longstanding uncertainty about possible adverse effects of cervical procedures on pregnancy, reported Allison Naleway, PhD, of Kaiser Permanente Northwest, in Portland, Oregon, and colleagues.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Uncover Hereditary Cancer Risk for Your Patients
The average OB/GYN has 400 patients who meet criteria for further evaluation of hereditary cancer syndrome. Learn how to identify high-risk patients.
Advertise here!

To find out how to feature your company in the SGO News Brief and other advertising opportunities, Contact Geoffrey Forneret at 469-420-2629.


Researchers suggest new therapy for BRCA-related tumors
Breast Cancer News
According to a study published in Nature, BRCA1 and BRCA2 genes are known to produce tumor suppressor proteins that help repair damaged DNA, ensuring the integrity of the genetic material. When one or both of these genes suffer mutations, their encoding protein may no longer be produced or have its function compromised, potentially resulting in a defective DNA repair mechanism and increased risk for genetic alterations that may lead to cancer. It is well-known that if a woman inherits specific mutations in the BRCA1 or BRCA2 genes, her risk for developing breast and/or ovarian cancer is greatly increased.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Visit the SGO Women's Cancer News archive page.

Model improves prediction of breast cancer risk after benign biopsy
A model that consisted of demographic and histologic features more accurately reflected a woman’s risk for breast cancer after receipt of a benign biopsy than the Breast Cancer Risk Assessment Tool, according to study results published in the Journal of Clinical Oncology. “Physicians routinely perform biopsies to evaluate concerning findings in the breast, either felt on exam or seen on mammogram, for the presence of a breast cancer,” researcher Amy Degnim, MD, a surgeon at Mayo Clinic in Rochester, Minnesota, said in a press release. “However, about three-quarters of these biopsies prove to be benign and are referred to as benign breast disease.”
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Women's Cancer News
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Jessica Taylor, Senior Medical Editor, 202-684-7169  
Contribute news

Inclusion of advertisements does not constitute SGO endorsement of company products or services.

Be sure to add us to your address book or safe sender list so our emails get to your inbox. Learn how.

This edition of the Women's Cancer News was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!

Recent issues

Feb. 11, 2015
Feb. 4, 2015
Jan. 28, 2015
Jan. 21, 2015

7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063